SCHEMBL20161728

SCHEMBL20161728

COc1ccc(Sc2cnc(N)s2)cc1C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TXK P42681 3/20 0.45
JAK3 P52333 3/20 0.45
BTK Q06187 1/20 0.45
ITK Q08881 3/20 0.43
ALDH1A1 P00352 3/20 0.40
NTRK1 P04629 3/20 0.39
LCK P06239 1/20 0.38
FYN P06241 1/20 0.38
KDM4E B2RXH2 1/20 0.37
HPGD P15428 1/20 0.37
MRGPRX4 Q96LA9 1/20 0.36
NEK2 P51955 2/20 0.36
NPC1 O15118 1/20 0.35
MITF O75030 1/20 0.35
LMNA P02545 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
P2RX3 P56373 1/20 0.35
P2RX2 Q9UBL9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29932895 1.00 TXK (0.45) TXKJAK3BTKITKALDH1A1
SCHEMBL20162004 0.82 MCL1 (0.48) ITKALDH1A1NTRK1KDM4EHPGD
SCHEMBL29932940 0.82 MCL1 (0.48) ITKALDH1A1NTRK1KDM4EHPGD
SCHEMBL29932902 0.80 JAK3 (0.47) TXKJAK3BTKITK
SCHEMBL5657783 0.80 JAK3 (0.47) TXKJAK3BTKITK
SCHEMBL29933029 0.73 POLB (0.56) ALDH1A1HPGDMRGPRX4SMN1; SMN2
SCHEMBL27085710 0.73 POLB (0.56) ALDH1A1HPGDMRGPRX4SMN1; SMN2
SCHEMBL9426921 0.73 POLB (0.51) ALDH1A1KDM4EHPGDNPC1LMNA
SCHEMBL5658462 0.72 ITK (0.44) ITKALDH1A1NTRK1KDM4EHPGD
SCHEMBL29690741 0.71 POLB (0.33) TXKJAK3BTKITKALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11897874-B2 Compounds and methods for modulating Interleukin-2-inducible T-cell kinase CORVUS PHARMACEUTICALS, INC. (US) 2024-02-13 US disclosed
US-11897874-B2 Compounds and methods for modulating Interleukin-2-inducible T-cell kinase CORVUS PHARMACEUTICALS, INC. (US) 2024-02-13 US disclosed
US-11897874-B2 Compounds and methods for modulating Interleukin-2-inducible T-cell kinase CORVUS PHARMACEUTICALS, INC. (US) 2024-02-13 US disclosed
US-20220363676-A1 COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE CORVUS PHARMACEUTICALS, INC. 2022-11-17 US disclosed
EP-3534899-B1 COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE CORVUS PHARMACEUTICALS INC (US) 2022-06-01 EP disclosed
US-11008314-B2 Compounds and methods for modulating interleukin-2-inducible t-cell kinase CORVUS PHARMACEUTICALS, INC. (US) 2021-05-18 US disclosed
WO-2018089261-A2 COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE CORVUS PHARMACEUTICALS, INC. (US) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11008314-B2 Compounds and methods for modulating interleukin-2-inducible t-cell kinase IL2, NFATC1, IL2RA TXK 201/4885JAK3 341/4885BTK 398/4885
US-20220363676-A1 COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE IL2, NFATC1, IL2RA TXK 201/4885JAK3 341/4885BTK 398/4885
US-11897874-B2 Compounds and methods for modulating Interleukin-2-inducible T-cell kinase IL2, NFATC1, IL2RA TXK 201/4885JAK3 341/4885BTK 398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.